Deutsche Bank’s downgrade of Novo Nordisk (NVO) to Sell, following mixed second quarter results and obesity drug setbacks, has sharpened investor focus on the stock’s recent performance and current valuation. <\/p>\n
At a share price of US$47.19, Novo Nordisk has seen short term pressure build, with the share price return down 3.0% over the last day and about 5.0% over the past month. The year to date share price return is down 9.9% and the 1 year total shareholder return is down 13.5%, indicating that recent news on obesity drug developments has come against an already fading longer term trend. <\/p>\n
Compare Novo Nordisk’s recent downgrade and price pressure with other large, cash generating companies by scanning the curated list of solid balance sheet and fundamentals (51 results)<\/a> for potential alternatives in similar conditions. <\/p>\n After a sharp pullback and a fresh Sell rating, investors in Novo Nordisk now need to weigh whether the recent weakness has created remaining upside or whether the best of the stock’s rerating is already behind it. <\/p>\n Most Popular Narrative: 54.2% Undervalued <\/p>\n Novo Nordisk’s most followed narrative points to a fair value of $102.97 per share versus the recent close at $47.19, which frames the recent weakness very differently to the fresh Sell call. <\/p>\n The GLP-1 market is growing at an unprecedented rate, with global sales projected to more than double from 2025 levels to reach $190 billion to $200 billion by 2035, with some forecasts projecting the market to exceed $250 billion by 2030-2034 due to the expansion into new therapeutic areas and rapid adoption of oral treatments. <\/p>\n Read the complete narrative. Read the complete narrative.<\/a> <\/p>\n Want to see what is driving that $102.97 fair value? The narrative leans heavily on GLP-1 growth, firmer margins, and a future profit multiple that assumes sustained strength. Curious how those moving parts add up at a discount rate that aims to be conservative yet still supports a much higher price tag. <\/p>\n Result: Fair Value of $102.97 (UNDERVALUED) <\/p>\n Have a read of the narrative in full and understand what’s behind the forecasts.<\/a> <\/p>\n However, this upbeat Novo Nordisk narrative could be knocked off course if GLP-1 growth expectations prove too optimistic, or if regulatory decisions on key drugs disappoint. <\/p>\n Find out about the key risks to this Novo Nordisk narrative.<\/a> <\/p>\n Next Steps <\/p>\n With sentiment on Novo Nordisk clearly mixed, consider quickly reviewing both the concerns and the potential upside to form your own view using the 3 key rewards and 2 important warning signs<\/a>. <\/p>\n Looking for more investment ideas beyond Novo Nordisk? <\/p>\n If Novo Nordisk has sharpened your focus on valuation and risk, do not stop here. Broaden your watchlist now or you could miss other compelling setups. <\/p>\n This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n Companies discussed in this article include NVO<\/a>. <\/p>\n Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Deutsche Bank’s downgrade of Novo Nordisk (NVO) to Sell, following mixed second quarter results and obesity drug setbacks,…\n","protected":false},"author":2,"featured_media":154233,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[1147,272,948,1739],"class_list":["post-154232","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-fair-value","tag-novo-nordisk","tag-share-price","tag-total-shareholder-return"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117169336123567348","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/154232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=154232"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/154232\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/154233"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=154232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=154232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=154232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}